Grifois

GRFS

Market cap $5.96B

OTTAWA, March 30, 2026 (GLOBE NEWSWIRE) -- Proponents of public universal health care across Canada are calling for the closure of Grifols facilities in the wake of two deaths in Winnipeg of people who sold their plasma to the giant multinational. A third person is suing the hugely profitable Grifols for kidney damage from a plasma sale. Health Canada also reports non-compliance at four other Grifols sites.

Healthcare ​company Grifols ‌said ​on ​Tuesday it ⁠has ​approved ​a U.S. ​initial ​public offering of ‌its ⁠U.S. biopharma ​business.

BARCELONA, Spain, March 17, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today shared proof-of-concept data from its Chronos-PD program, demonstrating that biological changes in individuals with Parkinson's disease (PD) occur more than a decade before clinical diagnosis, with potential future implications for early detection and intervention.

TORONTO, March 13, 2026 (GLOBE NEWSWIRE) -- The Ontario and Manitoba Health Coalitions held a press conference this morning to respond to a  report from CBC  about two patients who died in Winnipeg after having their blood plasma harvested at centres owned by for-profit pharmaceutical corporation Grifols.  Another report followed, of a man who is suing , alleging kidney damage from equipment failure while having his plasma harvested at a Grifols centre. The Alberta Friends of Medicare  revealed that Grifols has been found non-compliant  with serious breaches at their Calgary centre. Inspection reports from Health Canada show that four Grifols centres have been found non-compliant in Calgary , Alberta; St. John , New Brunswick; and Regina and Saskatoon , Saskatchewan.

WINNIPEG, Manitoba and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- What: Spokespeople from the Manitoba Health Coalition and Ontario Health Coalition will respond to the sad news of two deaths of paid “donors” at for-profit plasma collection facilities owned by pharma giant Grifols. The Coalitions have long raised warnings about safety and the ownership and control of the blood system.

Grifols is a global leader in blood plasma, now rated 'BUY' with a €20/share PT and $23/share ADR target. GRFS has delivered €450M in cost savings, 150%+ net profit growth, and FCF exceeding guidance, with leverage down to 4.2x. Despite a BB- rating, improved fundamentals, dividend reinstatement, and forecasted 20–25% annual growth support a strong risk/reward profile.

Grifols, S.A. (GIKLY) Q4 2025 Earnings Call Transcript

Spanish drugmaker Grifols reported on Thursday a net profit of 402 million euros ($473.96 million) for 2025, more than double what it recorded the previous year, driven by revenues of 7.5 billion euros, up 7% from a year earlier.

White Falcon's top 5 positions for the White Falcon portfolio are precious metal royalty companies, AMD, NFI Group, EPAM, and Nu Holdings. Nu is likely to keep growing earnings at 30+% for many years to come and its stock price will likely follow. NFI currently trades at 11x this year's earnings and we think it can re-rate to 15-20x within the next two years.

Grifols, S.A. has executed a turnaround, with Q3 '25 results confirming improved fundamentals, reduced leverage, and restored dividend, supporting a renewed 'Buy' rating. GRFS now trades at a normalized P/E of 14-15x, but forward multiples drop below 9x, offering significant upside if growth forecasts materialize. Operational improvements include 7%+ revenue growth, double-digit EBITDA gains, positive FCF, and leverage below 4.3x, with further refinancing underway.